Suscribirse

Home NIV treatment quality in patients with chronic respiratory failure having participated to the French nationwide telemonitoring experimental program (The TELVENT study) - 15/09/23

Doi : 10.1016/j.resmer.2023.101028 
Sandrine Pontier-Marchandise a, , Joelle Texereau b, c, Arnaud Prigent d, Jésus Gonzalez-Bermejo e, f, Claudio Rabec g, Frédéric Gagnadoux h, Alexia Letierce i, Joao Carlos Winck j
a Department of Respiratory Medicine, Larrey Hospital, Toulouse University Hospital, Toulouse, France 
b Lung Function & Respiratory Physiology Units, Cochin University Hospital, AP-HP, Paris, France 
c VitalAire, Air Liquide Healthcare, Bagneux, France 
d Pulmonology Medical Group, Polyclinique Saint-Laurent, Rennes, France 
e Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, F-75005, Paris, France 
f AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, SSR respiratoire (Département R3S), F-75013, Paris, France 
g Pulmonary Department and Respiratory Critical Care Unit, Dijon University Hospital, Dijon, France 
h Department of Respiratory and Sleep Medicine, Angers University hospital and INSERM 1083, UMR CNRS 6015, MITOVASC, Equipe CarME, SFR ICAT, University of Angers, 49000 Angers, France 
i QualityStat – Morangis, France 
j Faculdade de Medicina da Universidade do Porto, Porto, Portugal 

Corresponding author at: Department of Respiratory Medicine, Larrey Hospital, CHU Toulouse, 24 chemin de Pouvourville, 31059 Toulouse, France.Department of Respiratory MedicineLarrey Hospital, CHU Toulouse24 chemin de PouvourvilleToulouse31059France

Abstract

Background

The ETAPES program is a national telemedicine experiment conducted in France between 2018 and 2023 to investigate whether home non-invasive ventilation (NIV) telemonitoring improves healthcare pathways in patients with chronic respiratory failure (CRF) and impacts healthcare organization. The program provides a combination of therapeutic education and NIV telemonitoring with data processed by an algorithm generating alerts. The TELVENT study objective was to analyze the evolution of ventilation quality in patients included in the ETAPES program.

Methods

Multicentric cohort study on patients undergoing long-term NIV included in the ETAPES program between September 2018 and December 2020 and who did not refuse the use of their data for this research. Data were obtained from homecare provider databases. The primary endpoint was to attain successful NIV treatment, which was determined by a combination of daily NIV usage for > 4 h per day, low leaks, and a low apnea-hypopnea index (AHI) identified by the NIV device. Respiratory disability was assessed using the DIRECT questionnaire.

Results

329 patients were included in the study of which 145 had COPD and 83 had started NIV and ETAPES within one-month delay. Approximately 25% of patients did not achieve the criteria for successful NIV at ETAPES entry. The proportion of patients with successful NIV treatment increased to 86.8% at six months (p = 0.003, Cochran-Armitage trend test) regardless of NIV history and continued to increase at 12 months in newly equipped NIV patients (93.8%, at month 12, p = 0.0026 for trend test). Over time, a significant increase in NIV use and compliance was observed, while AHI significantly decreased in the overall population. No significant decrease was observed for non-intentional leaks. Approximately 4.9 alerts were generated per patient per 6 months. Their number and type (low NIV use, high AHI or leaks) differed among patients based on their NIV history. Respiratory disability score decreased over time compared with baseline.

Conclusion

The TELVENT study highlights the importance of remote NIV monitoring to rapidly identify patients with unsuccessful ventilation. The combination of remote monitoring and therapeutic education may improve the quality of home NIV, especially in the first months of treatment.

El texto completo de este artículo está disponible en PDF.

Keywords : ETAPES, Telemonitoring, NIV, Chronic respiratory failure


Esquema


© 2023  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 84

Artículo 101028- novembre 2023 Regresar al número
Artículo precedente Artículo precedente
  • Recovery of Endothelium-dependent vascular relaxation impairment in convalescent COVID-19 patients: Insight from a pilot study
  • Fares Gouzi, Aurélien Philippe, Jean Pastre, Bertrand Renaud, Nicolas Gendron, Marielle Subileau, Thông Hua-Huy, Benjamin Planquette, Olivier Sanchez, David M. Smadja, Sven Günther
| Artículo siguiente Artículo siguiente
  • Eosinophil recovery in hospitalized COVID-19 patients is associated with lower rates of ICU admission and in-hospital mortality: An observational cohort analysis
  • Peter D. Yan, Daniela Markovic, Roxana Y. Hixson, Carolyn M. Shover, Russell G. Buhr, Ramin Salehi-Rad, Blake LeMaster, Donald P. Tashkin, Jennifer A. Fulcher, Igor Z. Barjaktarevic

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.